Drug Profile
MPI 674
Alternative Names: Femathina; MPI 674Latest Information Update: 24 Dec 2021
Price :
$50
*
At a glance
- Originator Mount Sinai Hospital (Toronto); Wayne State University
- Developer Meditrina Pharmaceuticals
- Class Antineoplastics; Nitriles; Small molecules; Triazoles
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Menstruation disorders
Most Recent Events
- 06 Feb 2008 Meditrina Pharmaceuticals has completed a global licensing agreement with AstraZeneca for aromatase inhibitors
- 12 Apr 2007 Phase-II clinical trials in Menstruation disorders in USA (PO)